Cyclooxygenase inhibition in early onset of tumor growth and related angiogenesis evaluated in EP1 and EP3 knockout tumor-bearing mice

Folkman J. (1971) Tumor angiogenesis: Therapeutic implications. N Engl J Med 285:1182–6 Gasparini G, Longo R, Fanelli M, Teicher BA (2005). Combination of antiangiogenic therapy with other anticancer therapies: Results, challenges, and open questions. J Clin Oncol 23: 1295–311 Peterson HI (1986). Tumor angiogenesis inhibition by prostaglandin synthetase inhibitors. Anticancer Res 6:251–3 Wang HM, Zhang GY (2005). Indomethacin suppresses growth of colon cancer via inhibition of angiogenesis in vivo. World J Gastroenterol 11: 340–3 Cahlin C, Korner A, Axelsson H et al. (2000). Experimental cancer cachexia: The role of host-derived cytokines interleukin (IL)-6, IL-12, interferon-gamma, and tumor necrosis factor alpha evaluated in gene knockout, tumor-bearing mice on C57 Bl background and eicosanoid-dependent cachexia. Cancer Res 60: 5488–93 Peluffo GD, Stillitani I, Rodriguez VA et al. (2004). Reduction of tumor progression and paraneoplastic syndrome development in murine lung adenocarcinoma by nonsteroidal antiinflammatory drugs. Int J Cancer 110: 825–30 McMillan DC, Leen E, Smith J, et al. (1995). Effect of extended ibuprofen administration on the acute phase protein response in colorectal cancer patients. Eur J Surg Oncol 21: 531–4 Gelin J, Andersson C, Lundholm K (1991). Effects of indomethacin, cytokines, and cyclosporin A on tumor growth and the subsequent development of cancer cachexia. Cancer Res 51: 880–5 Cahlin C, Gelin J, Delbro D et al. (2000). Effect of cyclooxygenase and nitric oxide synthase inhibitors on tumor growth in mouse tumor models with and without cancer cachexia related to prostanoids. Cancer Res 60: 1742–9 Lönnroth C, Svaninger G, Gelin J, et al. (1995). Effects related to indomethacin prolonged survival and decreased tumor growth in a mouse tumor model with cytokine dependent cancer cachexia. Int J Oncol 7: 1405–13 Lundholm K, Gelin J, Hyltander A, et al. (1994). Anti-inflammatory treatment may prolong survival in undernourished patients with metastatic solid tumors. Cancer Res 54: 5602–6 Lundholm K, Daneryd P, Korner U et al. (2004). Evidence that long-term COX-treatment improves energy homeostasis and body composition in cancer patients with progressive cachexia. Int J Oncol 24: 505–12 Rajendran JG, Krohn KA (2005). Imaging hypoxia and angiogenesis in tumors. Radiol Clin North Am 43: 169–87 Cahlin C, Gelin J, Andersson M et al. The effects of non-selective, preferential-selective and selective COX-inhibitors on the growth of experimental and human tumors in mice related to prostanoid receptors. Int J Oncol 2005; 27: 913–23 Lönnroth C, Andersson M, Lundholm K (2001). Indomethacin and telomerase activity in tumor growth retardation. Int J Oncol 18: 929–937 Ushikubi F, Segi E, Sugimoto Y, et al. (1998). Impaired febrile response in mice lacking the prostaglandin E receptor subtype EP3. Nature 395: 281–4 Batshake B, Sundelin J (1996). The mouse genes for the EP1 prostanoid receptor and the PKN protein kinase overlap. Biochem Biophys Res Commun 227: 70–6 Wang W, Andersson M, Lönnroth C et al. (2005). Anorexia and cachexia in prostaglandin EP1 and EP3 subtype receptor knockout mice bearing a tumor with high intrinsic PGE2 production and prostaglandin related cachexia. J Exp Clin Cancer Res 24: 99–107 Axelsson H, Bagge U, Lundholm K, Svanberg E (1997). A one-piece plexiglass access chamber for subcutaneous implantation in the dorsal skin fold of the mouse. Int J Microcirc Clin Exp 17: 328–9 Sales KJ, Katz AA, Howard B et al. (2002). Cyclooxygenase-1 is up-regulated in cervical carcinomas: Autocrine/paracrine regulation of cyclooxygenase-2, prostaglandin e receptors, and angiogenic factors by cyclooxygenase-1. Cancer Res 62: 424–32 Needleman P, Turk J, Jakschik BA et al. (1986). Arachidonic acid metabolism. Annu Rev Biochem 55: 69–102 Halushka PV, Mais DE, Mayeux PR, Morinelli TA (1989). Thromboxane, prostaglandin and leukotriene receptors. Annu Rev Pharm Tox 10: 213–39 Narumiya S, FitzGerald GA (2001). Genetic and pharmacological analysis of prostanoid receptor function. J Clin Invest 108: 25–30 Taketo MM (1998). Cyclooxygenase-2 inhibitors in tumorigenesis (part I). J Natl Cancer Inst 90: 1529–36 Watson AJ (1998). Chemopreventive effects of NSAIDs against colorectal cancer: Regulation of apoptosis and mitosis by COX-1 and COX-2. Histol Histopathol 13: 591–7 Palayoor ST, Tofilon PJ, Coleman CN (2003). Ibuprofen-mediated reduction of hypoxia-inducible factors HIF-1α and HIF-2α in prostate cancer cells. Clin Cancer Res 9: 3150–7 Kragh M, Hjarnaa PJ, Bramm E et al. (2003). In vivo chamber angiogenesis assay: An optimized Matrigel plug assay for fast assessment of anti-angiogenic activity. Int J Oncol 22:305–11 Raut CP, Nawrocki S, Lashinger LM et al. Celecoxib inhibits angiogenesis by inducing endothelial cell apoptosis in human pancreatic tumor xenografts. Cancer Biol Ther 2004; 3 Jones MK, Wang H, Peskar BM, et al (1999). Inhibition of angiogenesis by nonsteroidal anti-inflammatory drugs: Insight into mechanisms and implications for cancer growth and ulcer healing. Nat Med 5:1418–23 Castro MR, Lutz D, Edelman JL (2004). Effect of COX inhibitors on VEGF-induced retinal vascular leakage and experimental corneal and choroidal neovascularization. Exp Eye Res 79:275–85 Pearce HR, Kalia N, Bardhan KD, Brown NJ (2003). Effects of aspirin and indomethacin on endothelial cell proliferation in vitro. J Gastroenterol Hepatol 18:1180–7 Szabo IL, Pai R, Soreghan B, et al. (2001). NSAIDs inhibit the activation of egr-1 gene in microvascular endothelial cells. A key to inhibition of angiogenesis? J Physiol Paris 95: 379–83 Davel LE, Rimmaudo L, Espanol A, et al. (2004). Different mechanisms lead to the angiogenic process induced by three adenocarcinoma cell lines. Angiogenesis 7: 45–51 Chen JJ, Yao PL, Yuan A, et al. (2003). Up-regulation of tumor interleukin-8 expression by infiltrating macrophages: Its correlation with tumor angiogenesis and patient survival in non-small cell lung cancer. Clin Cancer Res 9: 729–37 Golab J, Kozar K, Kaminski R, et al. (2000). Interleukin 12 and indomethacin exert a synergistic, angiogenesis-dependent antitumor activity in mice. Life Sci 66: 1223–30 Lala PK, Al-Mutter N, Orucevic A (1997). Effects of chronic indomethacin therapy on the development and progression of spontaneous mammary tumors in C3H/HEJ mice. Int J Cancer 73: 371–80 Spisni E, Manica F, Tomasi V (1992). Involvement of prostanoids in the regulation of angiogenesis by polypeptide growth factors. Prostaglandins Leukot Essent Fatty Acids 47: 111–5 Chang SH, Liu CH, Conway R, et al. (2004). Role of prostaglandin E2-dependent angiogenic switch in cyclooxygenase 2-induced breast cancer progression. Proc Natl Acad Sci USA 101: 591–6 Gallo O, Franchi A, Magnelli L, et al. (2001). Cyclooxygenase-2 pathway correlates with VEGF expression in head and neck cancer. Implications for tumor angiogenesis and metastasis. Neoplasia 3: 53–61 Pai R, Szabo IL, Kawanaka H et al. (2000). Indomethacin inhibits endothelial cell proliferation by suppressing cell cycle proteins and PRB phosphorylation: A key to its antiangiogenic action? Mol Cell Biol Res Commun 4: 111–6 Li G, Yang T, Yan J (2002). Cyclooxygenase-2 increased the angiogenic and metastatic potential of tumor cells. Biochem Biophys Res Commun 299: 886–90 Sawaoka H, Tsuji S, Tsujii M, et al. (1999). Cyclooxygenase inhibitors suppress angiogenesis and reduce tumor growth in vivo. Lab Invest 79: 1469–77 Fosslien E (2000). Biochemistry of cyclooxygenase (COX)-2 inhibitors and molecular pathology of COX-2 in neoplasia. Crit Rev Clin Lab Sci 37: 431–502 Watanabe K, Kawamori T, Nakatsugi S, et al. (1999). Role of the prostaglandin E receptor subtype EP1 in colon carcinogenesis. Cancer Res 59: 5093–6 Franzese O, Comandini A, Cannavo E, et al. (1998). Effect of prostaglandin A1 on proliferation and telomerase activity of human melanoma cells in vitro. Melanoma Res 8: 323–8 Ogino M, Hisatomi H, Murata M, Hanazono M (1999). Indomethacin suppresses the growth of colon 26, Meth-A and FM3A tumors in mice by reducing the prostaglandin E2 content and telomerase activity in tumor tissues. Jpn J Cancer Res 90: 758–64 You BJ, Huang IJ, Liu WH et al. (1999). Decrease in nucleophosmin/B23 mRNA and telomerase activity during indomethacin-induced apoptosis of gastric KATO-III cancer cells. Naunyn Schmiedebergs Arch Pharmacol 360: 683–90 Amano H, Hayashi I, Endo H, et al. (2003). Host prostaglandin E(2)-EP3 signaling regulates tumor-associated angiogenesis and tumor growth. J Exp Med 197: 221–32 Takafuji V, Cosme R, Lublin D et al. (2000). Prostanoid receptors in intestinal epithelium: Selective expression, function, and change with inflammation. Prostaglandins Leukot Essent Fatty Acids 63: 223–35 Dirkx AE, Oude Egbrink MG, Kuijpers MJ, et al. (2003). Tumor angiogenesis modulates leukocyte-vessel wall interactions in vivo by reducing endothelial adhesion molecule expression. Cancer Res 63: 2322–9 Fukumura D, Salehi HA, Witwer B et al. (1995). Tumor necrosis factor alpha-induced leukocyte adhesion in normal and tumor vessels: Effect of tumor type, transplantation site, and host strain. Cancer Res 55: 4824–9